Phase 3 Clinical Trials With Primary Completion Dates in July 2020

This is a list of Phase 3 trials with primary completion dates in July 2020 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
AMAG AMAG Pharmaceuticals, Inc. 2020-07-01 Phase 3 NCT03893045 A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects
AMPE Ampio Pharmaceuticals, Inc. 2020-07-01 Phase 3 NCT03988023 Study of Ampion for the Treatment of Pain and Function in Patients With Severe Osteoarthritis of the Knee.
AXSM Axsome Therapeutics, Inc. 2020-07-01 Phase 3 NCT04039022 Open-Label Safety Study of AXS-05 in Subjects With Depression
EXEL Exelixis, Inc. 2020-07-01 Phase 3 NCT03690388 A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy
MCRB Seres Therapeutics, Inc. 2020-07-01 Phase 3 NCT03183128 ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection
MEDP Medpace Holdings, Inc. 2020-07-01 Phase 3 NCT03464019 Efficacy and Safety of Etripamil for the Termination of Spontaneous PSVT. NODE-301
MIST Milestone Pharmaceuticals Inc. 2020-07-01 Phase 3 NCT03464019 Efficacy and Safety of Etripamil for the Termination of Spontaneous PSVT. NODE-301
MYL Mylan N.V. 2020-07-01 Phase 3 NCT04344041 COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial)
NKTR Nektar Therapeutics 2020-07-01 Phase 3 NCT02915744 A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
OCGN Ocugen, Inc. 2020-07-01 Phase 3 NCT03591874 Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease
ONPH Oncology Pharma Inc. 2020-07-01 Phase 3 NCT02819960 Prevention of Irinotecan Induced Diarrhea by Probiotics
OTLK Outlook Therapeutics, Inc. 2020-07-01 Phase 3 NCT03844074 A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
RTRX Retrophin, Inc. 2020-07-01 Phase 3 NCT03041116 Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN Patients
VNDA Vanda Pharmaceuticals Inc. 2020-07-01 Phase 3 NCT04028492 Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis
VSTM Verastem, Inc. 2020-07-01 Phase 3 NCT02049515 A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07
ZGNX Zogenix, Inc. 2020-07-01 Phase 3 NCT02826863 A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome
ZGNX Zogenix, Inc. 2020-07-01 Phase 3 NCT02682927 A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome